Elizabeth Homans - Jun 16, 2021 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Executive Officer, Director
Signature
/s/ Heather Turner, as Attorney-in-fact
Stock symbol
LYEL
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
6/16/2021, 07:16 PM
Next filing
Sep 14, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LYEL Option (right to buy) Jun 16, 2021 Common Stock 3.47M $0.10 Direct F1
holding LYEL Option (right to buy) Jun 16, 2021 Common Stock 694K $0.10 Direct F2
holding LYEL Option (right to buy) Jun 16, 2021 Common Stock 230K $3.65 Direct F3
holding LYEL Option (right to buy) Jun 16, 2021 Common Stock 3.35M $5.81 Direct F4
holding LYEL Option (right to buy) Jun 16, 2021 Common Stock 584K $6.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares vested on September 17, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
F2 1/4 of the option shares vested on November 6, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
F3 The shares vest in equal monthly installments over the forty-eight months following February 1, 2020.
F4 The shares vest in equal monthly installments over the forty-eight months following August 1, 2020.
F5 The shares vest in equal monthly installments over the forty-eight months following February 12, 2021.